JUL 13, 2017 6:25 PM PDT

Preliminary Approval Issued for Personalized Cancer Therapy

WRITTEN BY: Carmen Leitch

A committee of experts appointed by the Food and Drug Administration (FDA) has approved an experimental personalized therapy, in a first for the United States. In a clinical trial of patients suffering from severe cases of acute lymphoblastic leukemia (ALL), 83 percent of them were free of cancer after three months. Final approval, expected from the FDA on October 3, could be life-changing for those suffering from ALL. 

Bone marrow smear (large magnification) from a patient with acute lymphoblastic leukemia / Credit: WikimediaCommons/Furfur

The treatment, called CTL019, harvests a patient’s white blood cells and genetically reprograms them so that they will become cancer-fighting machines. Specifically, after being removed from the patient, T cells are engineered to express a receptor that will recognize a particular antigen that is indicative of cancerous cells. A patient's natural defense mechanisms can now be used against cancer.

"The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO of Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review."

This particular treatment was developed by Novartis, although other companies are making their forays into this area. Kita Pharma is awaiting their own approval decision on November 29. The video below explains more about this milestone.

Novartis worked with Penn University to create this treatment, which could be a new avenue for kids facing limited options. ALL is responsible for around 25 percent of all childhood cancer diagnoses. For patients that experience multiple relapses, the five-year disease-free survival rate drops to around 20 percent.

"It is encouraging to see the FDA panel's recommendation and continued momentum behind this innovative therapy, which has potential to help young patients with relapsed/refractory B-cell ALL," said the Penn team's leader, Carl June, MD, the Richard W. Vague Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at Penn. "We look forward to continuing to work with Novartis to help make a lasting impact on the way this disease is treated."

"We know firsthand from treating children and young adults with relapsed/refractory B-cell ALL that they desperately need innovative medicines that provide a new approach to managing this aggressive disease," said Stephan Grupp, MD, PhD, the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at Penn, Director of the Cancer Immunotherapy Frontier Program and Chief of the Section of Cellular Therapy and Transplant at CHOP. "Today's vote in favor of CTL019 is a positive step, and we appreciate Novartis' commitment to pediatric patients."

 

Sources: STAT News, Novartis

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 03, 2021
Immunology
Junk Food Helps Bad Bacteria Thrive In the Gut, Promotes Inflammation
MAY 03, 2021
Junk Food Helps Bad Bacteria Thrive In the Gut, Promotes Inflammation
We know that processed foods like ice cream, potato chips, and candy bars in excess can cause people to pile on the poun ...
MAY 09, 2021
Genetics & Genomics
Another Neurodevelopmental Disorder is Discovered
MAY 09, 2021
Another Neurodevelopmental Disorder is Discovered
Researchers are identifying more rare disorders because of advances in genetic sequencing technologies, which have made ...
MAY 10, 2021
Genetics & Genomics
DNA Supercoiling is Found to Play a Role in Gene Expression
MAY 10, 2021
DNA Supercoiling is Found to Play a Role in Gene Expression
A cell has many ways to control gene expression, one of which is the structure of the genome itself; active genes have t ...
MAY 19, 2021
Genetics & Genomics
The Genetic Secrets of Long-Lived People
MAY 19, 2021
The Genetic Secrets of Long-Lived People
For 2019, the United Nations estimated that the average life expectancy for a person is 72.6 years of age. People that l ...
MAY 20, 2021
Genetics & Genomics
The rhAmpSeq™ CRISPR Analysis System for next-generation sequencing analysis of CRISPR edits
MAY 20, 2021
The rhAmpSeq™ CRISPR Analysis System for next-generation sequencing analysis of CRISPR edits
CRISPR genome editing generates double-stranded breaks (DSBs) in genomic DNA and is a targeted method by which to achiev ...
JUN 04, 2021
Cell & Molecular Biology
Even When They're Outside the Brain, Infections Worsen Alzheimer's
JUN 04, 2021
Even When They're Outside the Brain, Infections Worsen Alzheimer's
It's thought that inflammation is closely connected to cognitive decline, and neuroinflammation plays a role role in the ...
Loading Comments...